4DO8
| Crystal structure of the muscarinic toxin MT1 | Descriptor: | ACETATE ION, Muscarinic toxin 1, THIOCYANATE ION | Authors: | Fruchart-Gaillard, C, Mournier, G, Vera, L, Servent, D, Stura, E.A. | Deposit date: | 2012-02-09 | Release date: | 2012-06-27 | Last modified: | 2024-10-16 | Method: | X-RAY DIFFRACTION (1.802 Å) | Cite: | Engineering of three-finger fold toxins creates ligands with original pharmacological profiles for muscarinic and adrenergic receptors. Plos One, 7, 2012
|
|
3FEV
| Crystal structure of the chimeric muscarinic toxin MT7 with loop 1 from MT1. | Descriptor: | Fusion of Muscarinic toxin 1, Muscarinic m1-toxin1, SULFATE ION | Authors: | Stura, E.A, Menez, R, Mourier, G, Fruchart-Gaillard, C, Menez, A, Servant, D. | Deposit date: | 2008-12-01 | Release date: | 2009-12-22 | Last modified: | 2024-10-30 | Method: | X-RAY DIFFRACTION (1.3 Å) | Cite: | Engineering of three-finger fold toxins creates ligands with original pharmacological profiles for muscarinic and adrenergic receptors. Plos One, 7, 2012
|
|
3NEQ
| Crystal structure of the chimeric muscarinic toxin MT7 with loop 3 from MT1 | Descriptor: | SULFATE ION, Three-finger muscarinic toxin 7 | Authors: | Stura, E.A, Servent, D, Menez, R, Mournier, G, Menez, A, Fruchart-Gaillard, C. | Deposit date: | 2010-06-09 | Release date: | 2011-08-24 | Last modified: | 2023-09-06 | Method: | X-RAY DIFFRACTION (1.25 Å) | Cite: | Engineering of three-finger fold toxins creates ligands with original pharmacological profiles for muscarinic and adrenergic receptors. Plos One, 7, 2012
|
|
2VLW
| Crystal structure of the muscarinic toxin MT7 diiodoTYR51 derivative. | Descriptor: | ACETATE ION, MUSCARINIC M1-TOXIN1, SULFATE ION | Authors: | Menez, R, Granata, V, Mourier, G, Fruchart-Gaillard, C, Menez, A, Servant, D, Stura, E.A. | Deposit date: | 2008-01-17 | Release date: | 2008-10-14 | Last modified: | 2023-12-13 | Method: | X-RAY DIFFRACTION (1.39 Å) | Cite: | Different Interactions between Mt7 Toxin and the Human Muscarinic M1 Receptor in its Free and N-Methylscopolamine-Occupied States. Mol.Pharmacol., 74, 2008
|
|
7ANQ
| Complete PCSK9 C-ter domain in complex with VHH P1.40 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, Proprotein convertase subtilisin/kexin type 9, SULFATE ION, ... | Authors: | Ciccone, L, Legrand, P, Stura, E.A, Dive, V, Seidahn, N.G, Fruchart Gaillard, C. | Deposit date: | 2020-10-12 | Release date: | 2021-10-20 | Last modified: | 2024-02-07 | Method: | X-RAY DIFFRACTION (2.2 Å) | Cite: | Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: Functional regulation of LDLR levels. Mol Metab, 67, 2022
|
|